BrainQ Technologies Named to Fast Company’s Annual List of the Next Big Things in Tech
List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future
[Jerusalem, IL], November 28, 2023 — BrainQ Technologies, a pioneering company at the forefront of brain longevity therapeutics, announced that it has been named to Fast Company’s annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from healthcare and security to artificial intelligence and data.
“Stroke is the leading cause of long-term disability, affecting millions of patients worldwide. Our Fast Company nomination of BrainQ further reaffirms our mission and our journey to curing stroke disability” says Yotam Drechsler CEO and Co-founder of BrainQ.
“The Next Big Things in Tech is not just a look around the corner—it's a look around the corner after that,” says Brendan Vaughan, editor-in-chief of Fast Company. “These are the products and ideas that will define technological innovation for the rest of this decade and beyond—and solve some of the world's most pressing issues. We are thrilled to honor the organizations that are making them a reality.”
Click here to see the final list.
The Winter 2023/2024 issue of Fast Company is available online now and will hit newsstands on December 5.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.
About BrainQ
BrainQ is a pioneering brain longevity therapeutics company. The company has received an FDA Breakthrough Device Designation for its first product for Stroke disability.
Product Disclaimer: The product information and treatment claims discussed in this article are based on data from clinical studies. These products or treatments may not be approved or available in all regions. Individual treatment outcomes can vary and are not guaranteed. The mention of clinical trial results does not constitute an endorsement or guarantee of efficacy or safety for any individual. Availability and regulatory status are subject to regional differences. The product is currently approved only in the European Economic Area.
Medical Disclaimer: The information provided in this blog post is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. The content relates to devices manufactured by BRAIN.Q and is not a substitute for professional medical advice, consultation, or care from a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or the use of any medical device. Never disregard professional medical advice or delay in seeking it because of something you have read on this blog.
BRAIN.Q makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the information, products, services, or related graphics contained in this blog post for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will BRAIN.Q be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising out of, or in connection with, the use of this blog post.